New study shows a single biopsy could provide enough molecular information to guide individualized therapy for prostate cancer patients
Feb. 29, 2016
| By Sabrina Richards / Fred Hutch News Service
A new study from scientists at Fred Hutchinson Cancer Research Center and the University of Washington suggests metastatic prostate cancer may present just the pair of characteristics needed for precision oncology: Metastases from different patients varied widely in their genetic characteristics, and metastases within a single patient were remarkably similar.
Center statistical analyses show screening for PSA velocity can lead to unnecessary biopsies
March 14, 2011
New research has shown that change in PSA levels over time—known as PSA velocity—is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The study findings were published online Feb. 24 in the Journal of the National Cancer Institute. Fred Hutchinson Cancer Research Center researcher, Cathee Till of the Public Health Sciences Division, conducted statistical analyses.
SCCA finds noninvasive screening better for evaluating anomalies in women under 40
Dec. 14, 2009
Targeted breast ultrasound of suspicious areas of the breast is a safe, reliable and cost-effective alternative to invasive biopsies for women under age 40, according to two Seattle Cancer Care Alliance studies.
New statistical model may improve the ability to distinguish between cancerous and non-cancerous breast lesions and reduce the need for biopsies
Dec. 1, 2008
| By Dean Forbes
Dr. Wendy DeMartini and colleagues in the breast-imaging department at the Seattle Cancer Care Alliance developed a preliminary statistical model that breast radiologists could use eventually when deciding whether a lesion found on breast MRI is likely to be malignant or benign.
Study finds hormone therapy appears to increase frequency of abnormal mammograms, breast biopsies
Feb. 25, 2008
Fred Hutchinson Cancer Research Center's Dr. Anne McTiernan and colleagues from the Public Health Sciences Division and the Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center co-authored a study on the connection between combined hormone therapy use and breast-cancer detection.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.